Comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 1 Deficiency CN028786 and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
A metabolic disorder affecting the processing of leucine, an amino acid. Symptoms may include developmental delay, low blood sugar, and feeding problems. Dietary restrictions and supplementation are typically used in management.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
0-null
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-1-deficiency-CN028786 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Metabolic decompensation | May include low blood glucose, poor feeding, or illness-related metabolic stress; not universal. | Not a primary metabolic leucine disorder based on the supplied description. | High |
| Developmental delay | May occur with the metabolic disorder, but timing and severity are not established here. | May occur with behavioral concerns and variable physical features. | Low |
| Physical or behavioral features | No characteristic congenital pattern is established by the source data. | May include developmental, behavioral, and physical features from chromosome 17 duplication. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 when
Abnormal leucine-related metabolic testing
Supports consideration of a metabolic disorder rather than a chromosomal syndrome.
Moderate
Hypoglycemia or feeding problems during illness
Fits the described metabolic presentation, but requires confirmatory testing.
Moderate
Need for dietary and supplement management
Management is typically metabolic; exact diet or doses are not established here.
Low
Choose 17q11 2 Microduplication Syndrome C3495679 when
Confirmed chromosome 17q11.2 duplication
Genetic confirmation distinguishes this congenital syndrome from a metabolic enzyme deficiency.
High
Developmental delay with behavioral concerns
This pattern is described for the syndrome, though it is not specific.
Moderate
Need for developmental early intervention
Supportive intervention is the stated focus rather than leucine restriction.
Moderate
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Metabolic evaluation | May show leucine-pathway abnormalities; exact cutoffs are not supplied. | No characteristic leucine-pathway abnormality is established. | An abnormal result suggests a metabolic process but is not itself a diagnosis. |
| Chromosomal microarray | Not expected to identify the enzyme deficiency. | May detect the 17q11.2 microduplication when present. | Genetic confirmation should be interpreted by a qualified clinician or geneticist. |
| Glucose assessment during illness | Low blood glucose may occur, without a universal threshold stated. | Hypoglycemia is not a defining feature in the source description. | Glucose abnormalities require clinical correlation and do not distinguish causes alone. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
- Outcome
- Chronic course is described, but individual outcome is not established.
- Factors
- Illness, feeding, metabolic control, and developmental needs may influence course.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Chronic course with generally moderate listed severity, but outcomes vary.
- Factors
- Developmental profile, behavior, associated features, and access to intervention may matter.
Time frame: Long-term; no reliable timeline is established from the source data.
Diagnosis confirmation, comorbidities, supportive care, and clinician follow-up.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic crisis | Possible concern during illness or poor intake; frequency is not established. Not described as a typical complication. Urgent assessment is appropriate for concerning symptoms. |
| Developmental impairment | Delay may occur; range and permanence are not established. Delay and behavioral concerns may occur with variable impact. Both warrant individualized developmental evaluation. |
| Feeding difficulty | Feeding problems are described and may affect nutrition. Not specifically established by the supplied description. Nutrition support should be tailored after clinical assessment. |
Patient education highlights
- HighDifferent causes
One condition affects leucine metabolism; the other is a chromosomal duplication. They are not interchangeable diagnoses.
- HighWhen to seek care
Poor feeding, lethargy, low blood glucose concerns, or developmental regression need prompt clinician review.
- MediumSupportive care
Metabolic care may include diet and supplements; the syndrome emphasizes early developmental intervention. Exact plans vary.